COMMUNIQUÉS West-GlobeNewswire

Seer Files ITC Complaint Against Nanomics
29/05/2026
Seeks Exclusion Order Barring Importation of Infringing Proteonano Kits and Workstations REDWOOD CITY, Calif., May 29, 2026 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), a pioneer and trusted partner for deep, unbiased [...]
At ASCO and EHA 2026, New Data Reinforce the Pivotal Role of clonoSEQ® MRD Testing Across Hematology Clinical Practice and Research
29/05/2026
Over 30 scientific presentations leverage clonoSEQ MRD testing to assess novel therapies and support MRD-guided patient care across blood cancers SEATTLE, May 29, 2026 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies [...]
New TECVAYLI®▼ (teclistamab) data demonstrate superior progression-free and overall survival versus standard of care as early as first relapse in multiple myeloma
29/05/2026
MajesTEC-9 is the second positive Phase 3 study to reinforce the strength of Johnson & Johnson’s TECVAYLI ® as early as second line 1 TECVAYLI ® delivered deep and durable responses, with nearly two-thirds of [...]
Moleculin Presents ASCO 2026 Data Demonstrating No Detectable Cardiotoxicity with Annamycin Despite Exposure Levels Far Exceeding Conventional Anthracycline Limits
29/05/2026
Independent Cleveland Clinic Cardiac Review Supports Potential Best-in-Class Safety Profile as MIRACLE Phase 2b/3 Trial Advances HOUSTON, May 29, 2026 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc. , (Nasdaq: MBRX) (“ [...]
Spectral Medical Announces PMA Submission to U.S. FDA for PMX
29/05/2026
TORONTO, May 29, 2026 (GLOBE NEWSWIRE) -- Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late-stage theranostic company advancing therapeutic options for sepsis and septic shock, today announced the [...]
AEON Clinic Redefines Longevity with Premier NAD+ IV Therapy and Premium IV Drips in Dubai
29/05/2026
DUBAI, United Arab Emirates, May 29, 2026 (GLOBE NEWSWIRE) -- AEON Clinic, Dubai’s premier destination for advanced regenerative medicine and holistic wellness located at Atlantis The Royal, is elevating the city’s [...]
Tenaya Therapeutics to Participate in the Jefferies Global Healthcare Conference 2026
29/05/2026
SOUTH SAN FRANCISCO, Calif., May 29, 2026 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative [...]
Agios Provides Update on Phase 2b Trial of Tebapivat in Lower-Risk Myelodysplastic Syndromes
29/05/2026
Results did not meet predefined threshold to support further development in LR-MDS Tebapivat was well tolerated, with no new safety signals observed CAMBRIDGE, Mass., May 29, 2026 (GLOBE NEWSWIRE) -- Agios [...]
SRx Health Solutions Invests in Uber Technologies, Inc. and Provides Shareholders with Portfolio Update
29/05/2026
Reduced long position in Compass, Inc., reduced short exposure to Bitcoin and added selective hedges in select international markets EMJX stress model turned STRESS from MIXED this week – the first negative market [...]
Dr. Kamalesh Sets New Benchmarks for Urological Surgery in the UAE: Minimally Invasive, Maximum Results!
29/05/2026
DUBAI, United Arab Emirates, May 29, 2026 (GLOBE NEWSWIRE) -- Recognized as one of the best urologists in Dubai , Dr. Kamalesh is raising the standard for patient care as the UAE enters the hotter summer months, a [...]
Sparrow Pharmaceuticals to Present Phase 2a Results for Clofutriben in Type 2 Diabetes at the 2026 American Diabetes Association (ADA) Scientific Session
29/05/2026
BOSTON, May 29, 2026 (GLOBE NEWSWIRE) -- Sparrow Pharmaceuticals , a targeted cardiometabolic therapeutics company, today announced the presentation of results describing Phase 2a efficacy and safety data in patients [...]
SAB BIO to Present Data on SAB-142 at The American Diabetes Association’s 2026 Scientific Sessions and FOCIS 2026 Annual Meeting
29/05/2026
Data will highlight deeper mechanistic insights and long-term dosing potential of SAB-142, a fully human multi-specific ATG for newly diagnosed Stage 3 T1D MIAMI, May 29, 2026 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, [...]
SkyAI Appoints Veteran Finance Executive Arthur Levine as Chief Financial Officer
29/05/2026
Mission-critical appointment with extensive public company, multinational, and emerging growth experience as SkyAI advances its agentic finance platform Marks the latest step in the Company’s evolution as it continues [...]
BioNexus Gene Lab Corp. Calls for Malaysia–China Biotechnology Cooperation to Move Beyond Trade into Co-Development
29/05/2026
KUALA LUMPUR, Malaysia, May 29, 2026 (GLOBE NEWSWIRE) -- BioNexus Gene Lab Corp. (Nasdaq: BGLC) (“BioNexus” or the “Company”), a technology-focused company advancing innovation across biotechnology, precision [...]
Replimune Announces Planned RP1 BLA Resubmission Following Productive Discussion with FDA
29/05/2026
WOBURN, Mass., May 29, 2026 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical-stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced that following [...]
Omniscient Secures USD 27.2M Series D to Accelerate Commercialization of AI-Enabled Brain Technology
29/05/2026
Funding to scale FDA-cleared Quicktome® platform and drive next-generation personalized brain care globally SAN FRANCISCO, May 29, 2026 (GLOBE NEWSWIRE) -- Omniscient (o8t®), a pioneer in AI-driven brain analysis [...]
Tempest Therapeutics Announces Warrant Exercise for Approximately $2 Million in Gross Proceeds
29/05/2026
BRISBANE, Calif., May 29, 2026 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST) (the “Company”), a clinical-stage biotechnology company developing a pipeline of advanced CAR-T cell therapy product [...]
PetMed Express, Inc. to Report Fourth Quarter and Fiscal Year 2026 Financial Results on Tuesday, June 2, 2026
29/05/2026
DELRAY BEACH, Fla., May 29, 2026 (GLOBE NEWSWIRE) -- PetMed Express, Inc., dba PetMeds and parent company of PetCareRx, (Nasdaq: PETS) today announced it will report financial results for the fourth quarter and fiscal [...]
Imviva Biotech to Present Data from Clinical Studies of CTA313 and CTD402 Validating its ANSWER™ Allogeneic CAR-T Platform in Pediatric and Adult Patient Populations at EULAR and EHA 2026 Congresses
29/05/2026
BOSTON, May 29, 2026 (GLOBE NEWSWIRE) -- Imviva Biotech, a clinical-stage biotechnology company developing next-generation allogeneic CAR-T cell therapies, today announced that it will present data on CTA313, its [...]

Pages